Literature DB >> 12905057

Probability of mortality of critically ill cancer patients at 72 h of intensive care unit (ICU) management.

Jeffrey S Groeger1, Jill Glassman, David M Nierman, Susannah Kish Wallace, Kristen Price, David Horak, David Landsberg.   

Abstract

GOALS: To develop and validate a model for probability of hospital mortality for cancer patients at 72 h of intensive care unit (ICU) management. PATIENTS AND METHODS: This is an inception cohort study performed at four ICUs of academic medical centers in the United States. Defined continuous and categorical variables were collected on consecutive patients with cancer admitted to the ICU. A preliminary model was developed from 827 patients and then validated on an additional 415 patients. Multiple logistic regression modeling was used to develop the models, which were subsequently evaluated for discrimination and calibration. The main outcome measure is in-hospital death.
RESULTS: A probability of mortality model, which incorporates ten discrete categorical variables, was developed and validated. All variables were collected at 72 h of ICU care. Variables included evidence of disease progression, performance status before hospitalization, heart rate >100 beats/min, Glasgow coma score </=5, mechanical ventilation, arterial oxygen pressure/fractional inspiratory oxygen ( PaO(2)/FiO(2)) ratio <250, platelets <100 k/ micro l, serum bicarbonate (HCO(3))<20 mEq/l, blood urea nitrogen (BUN) >40 mg/dl, and a urine output of <150 ml for any 8 h in the previous 24 h. The p values for the fit of the preliminary and validation models were 0.535 and 0.354 respectively, and the areas under the receiver operating characteristic (ROC) curves were 0.809 and 0.820.
CONCLUSIONS: We report a multivariable logistic regression model to estimate the probability of hospital mortality in critically ill cancer patients at 72 h of ICU care. The model is comprised of ten unambiguous and readily available variables. When used in conjunction with clinical judgment, this model should improve discussions about goals of care of these patients. Additional validation in a community hospital setting is warranted.

Entities:  

Mesh:

Year:  2003        PMID: 12905057     DOI: 10.1007/s00520-003-0498-9

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  55 in total

1.  A bootstrap resampling procedure for model building: application to the Cox regression model.

Authors:  W Sauerbrei; M Schumacher
Journal:  Stat Med       Date:  1992-12       Impact factor: 2.373

2.  Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments.

Authors:  M Mazumdar; J R Glassman
Journal:  Stat Med       Date:  2000-01-15       Impact factor: 2.373

3.  Is intensive care justified for patients with haematological malignancies?

Authors:  F Brunet; J J Lanore; J F Dhainaut; F Dreyfus; J F Vaxelaire; S Nouira; T Giraud; A Armaganidis; J F Monsallier
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

Review 4.  Malignancy and renal disease.

Authors:  M Kapoor; G Z Chan
Journal:  Crit Care Clin       Date:  2001-07       Impact factor: 3.598

5.  Combining physician's subjective and physiology-based objective mortality risk predictions.

Authors:  J P Marcin; M M Pollack; K M Patel; U E Ruttimann
Journal:  Crit Care Med       Date:  2000-08       Impact factor: 7.598

6.  Effect of clinical outcomes data on intensive care unit utilization by bone marrow transplant patients.

Authors:  H L Paz; A Garland; M Weinar; P Crilley; I Brodsky
Journal:  Crit Care Med       Date:  1998-01       Impact factor: 7.598

7.  Precedents for meaningful recovery during treatment in a medical intensive care unit. Outcome in patients with hematologic malignancy.

Authors:  D P Schuster; J M Marion
Journal:  Am J Med       Date:  1983-09       Impact factor: 4.965

8.  Short-term outcome among patients with leukemia and lymphoma admitted to a medical intensive care unit.

Authors:  Y J Ashkenazi; B S Kramer; E Harman
Journal:  South Med J       Date:  1986-09       Impact factor: 0.954

9.  Factors affecting the performance of the models in the Mortality Probability Model II system and strategies of customization: a simulation study.

Authors:  B P Zhu; S Lemeshow; D W Hosmer; J Klar; J Avrunin; D Teres
Journal:  Crit Care Med       Date:  1996-01       Impact factor: 7.598

10.  Cardiopulmonary resuscitation in medical cancer patients: the experience of a medical intensive-care unit of a cancer centre.

Authors:  J P Sculier; E Markiewicz
Journal:  Support Care Cancer       Date:  1993-05       Impact factor: 3.603

View more
  5 in total

1.  Admission of advanced lung cancer patients to intensive care unit: a retrospective study of 76 patients.

Authors:  Claire Andréjak; Nicolas Terzi; Stéphanie Thielen; Emmanuel Bergot; Gérard Zalcman; Pierre Charbonneau; Vincent Jounieaux
Journal:  BMC Cancer       Date:  2011-05-02       Impact factor: 4.430

Review 2.  Performance of prognostic models in critically ill cancer patients - a review.

Authors:  Sylvia den Boer; Nicolette F de Keizer; Evert de Jonge
Journal:  Crit Care       Date:  2005-07-08       Impact factor: 9.097

3.  Is prolonged mechanical ventilation of cancer patients futile?

Authors:  Anne-Claire Toffart; Jean-François Timsit
Journal:  Crit Care       Date:  2013-09-20       Impact factor: 9.097

4.  Outcome of severe infections in afebrile neutropenic cancer patients.

Authors:  Ksenija Strojnik; Ksenija Mahkovic-Hergouth; Barbara Jezersek Novakovic; Bostjan Seruga
Journal:  Radiol Oncol       Date:  2016-02-10       Impact factor: 2.991

5.  Admission factors associated with hospital mortality in patients with haematological malignancy admitted to UK adult, general critical care units: a secondary analysis of the ICNARC Case Mix Programme Database.

Authors:  Peter A Hampshire; Catherine A Welch; Lawrence A McCrossan; Katharine Francis; David A Harrison
Journal:  Crit Care       Date:  2009-08-25       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.